Close Menu

NEW YORK – Ginkgo Bioworks and Berkeley Lights said today that they have inked a $150 million deal to incorporate Berkeley Lights' Beacon optofluidic platform into Ginkgo's automated genetic engineering foundries.

Under the multi-year, non-exclusive deal, Boston-based Ginkgo will acquire Beacon platforms from Emeryville, California-based Berkeley Lights and fund the development of workflows to use them in a variety of microbial and mammalian organisms, a Ginkgo spokesperson said in an email.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Washington Post reports that a US Senate committee voted this week to approve the nomination of Stephen Hahn to lead the Food and Drug Administration.

Nature News reports that gene therapy approaches are tackling sickle cell disease, but that the cost of treatment is a concern.

One gene regulates hundreds of others to influence facial development, according to New Scientist.

In Nature this week: resources for single-cell analysis, little overlap in the microRNAs used by Salmonella and Shigella to infect host cells, and more.